Research proposal investigating whether weekly UV-C light exposure (254nm, 5 minutes) can boost resveratrol and other phytoalexin production in peanut plants, increasing tolerance to Sclerotium rolfsii fungal infection. The approach offers a non-chemical disease management strategy for peanut cultivation.
Fungal pathogens such as Sclerotium rolfsii pose significant challenges to peanut production worldwide. This research proposes a novel, non-chemical disease management approach: exposing peanut plants to short-duration UV-C light (254nm) on a weekly basis to stimulate the plant's natural defense mechanisms. The central hypothesis is that this treatment will upregulate the production of phytoalexins, particularly resveratrol, which are plant secondary metabolites with antimicrobial properties. Higher concentrations of these compounds are expected to reduce disease severity, including wilting and cell death, when plants are challenged by fungal pathogens.
This approach could offer peanut growers an alternative or complement to conventional fungicide programs, potentially reducing chemical inputs while maintaining crop health and yield.
Treatment protocol:
Delivery system:
Measurement and validation:
Expected outcomes:
This research is at an early experimental stage (TRL 2-3). The hypothesis is based on established findings that biotic and abiotic stresses can trigger phytoalexin production in plants, combined with recent proposals suggesting nighttime UV exposure as a viable elicitation method. Validation will be conducted in a controlled greenhouse environment at the University of Florida, with planned HPLC-based biochemical assays and disease progression monitoring through pod-set stage. The proposed tunnel-cart delivery system represents a prototype approach that would require further development and field-scale testing before commercial deployment.
The University of Florida is a comprehensive public research university with a broad academic and research portfolio and a statewide presence. Industry collaborates through co-located labs and shared core facilities and through an integrated academic health system that accelerates clinical translation. A statewide extension network and multiple research and education sites connect companies with field-scale testing and rapid deployment, while incubators and an adjacent innovation district provide pathways from lab to market. Research is supported by competitive funding from major federal agencies such as NIH, NSF, USDA, and DOE. A dedicated technology transfer office supports IP, licensing, and startup formation.